. 2017 Jan 18;2017:2924731. doi: 10.1155/2017/2924731

Table 2.

Main effects of COX-2 SNPs on LMCAD risk.

SNP	Genotyping value	Genotype	N		Unadjusted		Adjusted
SNP	Genotyping value	Genotype	LMCAD (%)	MPCAD (%)	OR (95% CI)	p value	OR (95% CI)	p value
rs5275	97.4%	TT	307 (64.6)	665 (64.6)	1.000 (0.796~1.255)	0.998	0.999 (0.795~1.256)	0.994
rs5275	97.4%	TC + CC	168 (35.4)	364 (35.4)	1.000 (0.796~1.255)	0.998	0.999 (0.795~1.256)	0.994
rs5277	99.9%	GG	432 (69.3)	977 (92.5)	1.575 (1.096~2.262)	0.014	1.590 (1.103~2.291)	0.013
rs5277	99.9%	GC + CC	55 (11.3)	79 (7.5)	1.575 (1.096~2.262)	0.014	1.590 (1.103~2.291)	0.013
rs689466	98.8%	AA	140 (28.9)	309 (29.7)	1.079 (0.827~1.406)	0.577	1.086 (0.831~1.420)	0.544
rs689466	98.8%	AG + GG	345 (71.1)	731 (70.3)	1.079 (0.827~1.406)	0.577	1.086 (0.831~1.420)	0.544

Values are n (%). CI, confidential interval; COX-2, cyclooxygenase-2; LMCAD, left main coronary artery disease; MPCAD, more peripheral coronary artery disease; OR, odds ratio; SNP, single nucleotide polymorphism.